UCB: EU approves label change for rheumatic diseases drug
(CercleFinance.com) - Belgium's UCB said on Tuesday that the European Medicines Agency (EMA) has approved label change for its best-selling drug Cymzia, making it the first anti-TNF for potential use in women with chronic rheumatic disease, both during pregnancy and breastfeeding.
Chronic rheumatic diseases, such as rheumatoid arthritis and psoriatic arthritis, are frequently seen in women of childbearing age, with rheumatoid arthritis, and affect three times as many women as men.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
Chronic rheumatic diseases, such as rheumatoid arthritis and psoriatic arthritis, are frequently seen in women of childbearing age, with rheumatoid arthritis, and affect three times as many women as men.
Copyright (c) 2018 CercleFinance.com. All rights reserved.